{
  "docId": "019de075-7a24-71be-ac51-dd13871aea0a",
  "docSlug": "fd7a76edfe86a80da6108d342915286a",
  "documentTitle": "BioAtla | Investor Presentation Deck | 43 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 38,
  "pageCount": 43,
  "prevPage": 37,
  "nextPage": 39,
  "slideType": "solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "The slide uses a before-after-bridge style comparison between the problem (toxicity) and the solution (BA3182).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-7a24-71be-ac51-dd13871aea0a/38",
  "deckHref": "/decks/019de075-7a24-71be-ac51-dd13871aea0a",
  "deckJsonHref": "/decks/019de075-7a24-71be-ac51-dd13871aea0a.json",
  "deckAnchorHref": "/decks/019de075-7a24-71be-ac51-dd13871aea0a#slide-38",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.4,
        "x": 0.06,
        "y": 0.63
      },
      "kind": "chart",
      "text": "Tumor shrinkage",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9c9f5264-6920-4b72-acdb-f4afdec47f79",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.15,
        "y": 0.93
      },
      "kind": "disclaimer",
      "text": "MiXeno Model with HCT116 = Colorectal Cancer Cell Line; 1mg/kg twice/week in mice; *Single Dose - non-GLP Toxicity Study; WT = wild type; MTD = Maximum Tolerated Dose; TI = Therapeutic Index",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "405b2e41-45e3-46b8-9586-3146efb5a834",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.35,
        "x": 0.06,
        "y": 0.235
      },
      "kind": "list",
      "text": "EpCAM expressed on normal epithelial cells and overexpressed in a wide range of tumors (adenocarcinoma). CD3-bispecifics have demonstrated beneficial effects but hampered by dose-limiting toxicity, namely, cytokine release syndrome (CRS)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2cc99693-242f-431e-bb83-9279256fb706",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.35,
        "x": 0.53,
        "y": 0.2
      },
      "kind": "list",
      "text": "BA3182 exhibits efficient tumor shrinkage with superior safety profile. In non-GLP and GLP tox studies in NHP, dual selection results in high selectivity. 160-fold TI increase. MTD not reached. No Cytokine release observed.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ecd708db-8b1f-49d9-91e7-cfa6c7f25c09",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.4,
        "x": 0.53,
        "y": 0.63
      },
      "kind": "table",
      "text": "Safety Profile comparison of WT-EpCAM x WT-CD3 vs CAB-EpCAM x CAB-CD3",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "52af31f3-98cf-4086-b279-f249a8f2abab",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.6,
        "x": 0.03,
        "y": 0.14
      },
      "kind": "title",
      "text": "significant opportunity for safe and effective EpCAMxCD3 bispecific",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f4ec9602-4a20-4d6a-a163-cdde2c189cee",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.75,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "BA3182 – CAB-EpCAMxCAB-CD3 bispecific T-Cell Engager (TCE)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3a070c1c-c4b8-44e3-863e-45172655adf0",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "e34dc39f-633c-4bc4-9019-a652da2b1513",
      "evidence": "table/data: Safety Profile comparison of WT-EpCAM x WT-CD3 vs CAB-EpCAM x CAB-CD3",
      "confidence": 0.9
    }
  ],
  "frameworks": [
    {
      "name": "before-after-bridge",
      "slug": null,
      "matchId": "294efa49-a267-489e-a3ea-d9a616cf35c9",
      "evidence": "The slide contrasts the problem of toxicity in standard bispecifics with the solution of BA3182.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 40,
      "from": 8,
      "beatId": "e2a4fdc0-9030-4acb-8ef9-b3ca594561cc",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Roadmap",
      "beatSlug": null,
      "evidence": "The deck outlines a clear roadmap for BioAtla's pipeline and milestones",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}